Key Details
Price
$4.52Annual EPS
-$0.44Annual ROE
-380.20%Beta
0.93Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders.
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity. Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock.
Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Telo's MRD assays are being evaluated utilizing Adaptive Biotechnologies' clonoSEQ assay technology as a component of Telo's ongoing MRD clinical trial, TELO-DMRD (NCT05530096), being conducted with McGill University, Montreal, Canada.
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines
Telomir Pharmaceuticals plans to raise $7 million through an IPO to fund its development of treatments for age-related inflammatory conditions. The company's lead candidate, TELOMIR-1, has the potential to act as an Interleukin-17 inhibitor for conditions such as hemochromatosis and osteoarthritis. Given TELO's thin capitalization, high valuation expectations and early stage of development, my opinion on the IPO is to Sell [Avoid].
FAQ
- What is the primary business of Telomir Pharmaceuticals Common Stock?
- What is the ticker symbol for Telomir Pharmaceuticals Common Stock?
- Does Telomir Pharmaceuticals Common Stock pay dividends?
- What sector is Telomir Pharmaceuticals Common Stock in?
- What industry is Telomir Pharmaceuticals Common Stock in?
- What country is Telomir Pharmaceuticals Common Stock based in?
- When did Telomir Pharmaceuticals Common Stock go public?
- Is Telomir Pharmaceuticals Common Stock in the S&P 500?
- Is Telomir Pharmaceuticals Common Stock in the NASDAQ 100?
- Is Telomir Pharmaceuticals Common Stock in the Dow Jones?
- When was Telomir Pharmaceuticals Common Stock's last earnings report?
- When does Telomir Pharmaceuticals Common Stock report earnings?
- Should I buy Telomir Pharmaceuticals Common Stock stock now?